INTRODUCTION
Although allogeneic blood or marrow transplantation (BMT) is the only potentially curative approach for many patients with hematologic malignancies, the inability to identify a matched donor and the sometimes prohibitive delays with matched unrelated donor BMT 1 have historically been major barriers. In contrast, partially HLA-mismatched related, or HLA-haploidentical, donors can be promptly identified for most patients. HLAmismatched allografting used to be associated with excess risks of graft-versus-host disease (GVHD), graft failure, and nonrelapse mortality (NRM).
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However, modern approaches to GVHD prophylaxis, such as high-dose post-transplantation cyclophosphamide (PTCy), have greatly reduced the morbidity of HLA-haploidentical BMT (haplo-BMT), making it a viable alternative for patients lacking HLA-matched donors. 8, 9 As a pharmacologic form of tolerance induction, 10 high-dose PTCy moderates GVHD and graft
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failure as a result of the heightened chemotherapy sensitivity of proliferating, alloreactive T cells compared with nonalloreactive resting and memory T cells. 9,11 High-dose PTCy reduces GVHD (particularly grade 3 or 4 acute and chronic GVHD) and graft failure after T-cellreplete haploidentical allografting. [12] [13] [14] [15] [16] Moreover, greater HLA disparity does not seem to be detrimental to overall outcomes in nonmyeloablative (NMA) haplo-BMT using PTCy. 17 Although considered experimental in many centers, the use of NMA or reduced-intensity conditioned (RIC) haplo-BMT is growing as a result of its feasibility and safety. However, there is a paucity of data on the safety and efficacy of haplo-BMT in older patients, who are disproportionally affected by hematologic malignancies. 18, 19 Further, the incidence of hematologic malignancies in older patients seems to be increasing. 20 Here, we evaluated the effect of age on toxicity and survival outcomes after NMA haplo-BMT with high-dose PTCy, among patients age 50 to 75 years.
PATIENTS AND METHODS

Patients and Treatments
We retrospectively evaluated 271 consecutive patients with hematologic malignancies, age 50 to 75 years, who received NMA haplo-BMT with highdose PTCy at Johns Hopkins (Baltimore, MD) from January 2003 through June 2013. The study received institutional review board approval, and all participants gave signed informed consent for BMT. Transplantations were performed on prospective clinical trials (228 patients; 84%) or similarly off study, with reasons for off-study treatment including insurance limitations, completed protocol accrual, and rarely ineligibility. Forty-seven percent of patients were included in previous publications.
14,17 As a result of disease biology, allografting was prioritized over autografting for transformed lymphoma, de novo diffuse large B-cell lymphoma that relapsed less than 1 year after first-line therapy 21 or was chemotherapy-refractory, and T-cell lymphoma. Eligibility criteria for NMA BMT typically included Eastern Cooperative Oncology Group (ECOG) performance status (PS) Յ 2, left ventricular ejection fraction Ն 35%, forced expiratory volume in 1 second and forced vital capacity Ն 40% predicted (Ն 60% predicted after thoracic or mantle irradiation), and absence of uncontrolled infection. Morphologic complete remission for acute leukemia 22 and at least partial remission for aggressive lymphoma 23 were standardly required. Donors were first-degree relatives or half-siblings who shared one HLA haplotype and were mismatched at Ն one locus of the unshared haplotype based on high-resolution typing at HLA-A, -B, -Cw, -DRB1, and -DQB1. Donor selection criteria included, in order of priority, medical fitness, antidonor HLA antibody status, major ABO compatibility, matched cytomegalovirus (CMV) immunoglobulin G serostatus, overall ABO compatibility, and sex (male donor preferred for male patient).
All patients received cyclophosphamide (14.5 mg/kg per day intravenously [IV] on days Ϫ6 and Ϫ5), fludarabine (30 mg/m 2 per day IV on days Ϫ6 to Ϫ2, adjusted for renal function), total-body irradiation (2 Gy on day Ϫ1), and T-cell-replete allografting (on day 0) as previously described.
14 Fludarabine was dosed using actual weight, and pre-and post-transplantation cyclophosphamide was standardly dosed using the lesser of ideal and actual weight. All but one patient received a bone marrow graft. The median infused CD34 ϩ cell dose was 4.1 ϫ 10 6 /kg (interquartile range, 3.2 to 5.2 ϫ 10 6 /kg). GVHD prophylaxis consisted of high-dose PTCy (50 mg/kg per day IV on days 3 and 4) with mesna, mycophenolate mofetil (days 5 through 35), and tacrolimus.
14 In the absence of GVHD or graft failure, tacrolimus was planned from days 5 through 180 (224 patients; 83%), per our institutional standard, or days 5 through 90 (47 patients; 17%) on a clinical trial of reduced immunosuppression. Tacrolimus was dosed with a target trough of 5 to 15 ng/mL and discontinued without taper. Filgrastim was administered from day 5 until neutrophil recovery to Ն 1,000/L. Recipients of other allogeneic transplantation regimens and those undergoing second allogeneic transplantations were excluded.
Recipients of consolidative or maintenance therapy (eg, tyrosine kinase inhibitors) were included, with post-transplantation rituximab given for potential relapse reduction in 54 (42%) of 128 relevant patient cases.
Supportive care included a quinolone and Candida albicans prophylaxis from day 0 to neutrophil recovery and longer-term prophylaxis against Pneumocystis jirovecii and varicella-zoster virus. CMV-seronegative patients received transfusions from CMV-seronegative donors or leukoreduced products. CMV quantitative polymerase chain reaction was monitored weekly through at least day 60, and CMV reactivation was pre-emptively treated.
Nearly all transplantations (97%) were initiated in the outpatient setting, with hospitalization as necessary (commonly for febrile neutropenia during the night). Patients were observed until at least day 60 before discharge to the primary oncologist, standardly returning to Johns Hopkins at 6 months, 1 year, and then yearly after transplantation.
Definitions
Pretransplantation risk factors were scored using the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) 24 Graft failure was defined as persistent absence, or achievement then loss, of Ն 5% donor chimerism by approximately day 60 without detected bone marrow malignancy. Acute GVHD was graded by Keystone criteria. 27 Chronic GVHD was diagnosed by National Institutes of Health consensus criteria.
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Statistical Methods
The primary objective was to evaluate survival outcomes relative to age at BMT in patients age Ն 50 years. Primary analyses evaluated age as a categorical variable (age grouped by decade or age 50 to 59 v Ն 60 years), and secondary analyses evaluated age as a continuous variable. Group characteristics were compared with Kruskal-Wallis tests for continuous outcomes or Fisher's exact tests for categorical outcomes. Event-time distributions were measured from the date of BMT. Progression-free survival (PFS), disease-free survival, and overall survival (OS) were estimated using the Kaplan-Meier method and compared between groups with stratified log-rank statistics or Cox proportional hazard models, with stratification by BMT year (2003 to 2009 v 2010 to 2013). For PFS, failure was defined as relapse, progression, unplanned treatment of disease persistence, or death. For disease-free survival, failure was defined as disease persistence or death. Cumulative incidences (CuIs) of relapse/progression, NRM, GVHD, and count recovery were calculated or compared using Gray's k-sample tests or Fine and Gray's methods for competing risks.
29,30 PFS failures other than NRM were competing risks for NRM and vice versa; death was a competing risk for count recovery; and PFS failures and graft failure were competing risks for GVHD. All regression models for timeto-event end points were likewise stratified by BMT year. 31 Regression models were also adjusted for refined DRI group where specified. A hazard ratio Ͼ 1 indicates the increase in risk of having the event relative to the reference category. Significance was based on P Յ .05. All P values are two-sided and unadjusted for multiple comparisons. The database was locked on September 2, 2014, and analyzed using R, version 3.0.2.
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RESULTS
Patients and Overall Outcomes
Patient and transplantation characteristics are listed in Table 1 . In this cohort of 271 patients (median age, 61 years; range, 50 to 75 years), 115 patients (42%) were age 50 to 59 years at BMT, 129 (48%) were age 60 to 69 years, and 27 (10%) were age 70 to 75 years. Fifty-three percent of patients were five out of 10 HLA antigen matched, 71% were mismatched at all three class I loci, 74% were mismatched at both Age in HLA-Haploidentical BMT www.jco.org class II loci, and 89% were DRB1 mismatched. The most common diagnoses were aggressive non-Hodgkin lymphoma (NHL) and acute myeloid leukemia. Most patients (84%) had intermediate-risk or high-/very high-risk disease by refined DRI grouping. All patients with lymphoma had factors that were thought to make cure with autologous BMT unlikely. Of 27 patients with de novo diffuse large B-cell lymphoma, nine (33%) received prior autologous BMT; in most others, allogeneic BMT was prioritized because of short initial Thirty-six patients were high risk, and eight patients were very high risk.
i Antigen mismatching in any direction; composite of HLA-A, -B, -Cw, -DRB1, and -DQB1.
remission or chemotherapy refractoriness. Of seven Hodgkin lymphomas, four had treatment failure with autologous BMT, one was chemotherapy refractory, one was lymphocyte predominant, and one arose in the setting of chronic lymphocytic leukemia. When grouped by decade, the three patient age groups had similar histology (percent myeloid v lymphoid) and HCT-CI risk categories. Older donor age was statistically significantly associated with older patient age ( Table 1 ). All but one of the transplantations in patients age Ն 70 occurred after 2007.
Overall and age-specific outcomes are listed in Table 2 , and disease-specific outcomes are listed in Table 3 . The median follow-up time was 4.0 years (range, 0.02 to 10.2 years) overall by the reverse Kaplan-Meier method and 3.2 years (range, 0.4 to 10.2 years) among survivors. There was a 90% probability of neutrophil recovery by day 30 (median, 17 days) and an 85% probability of platelet recovery Ն 20,000/L by day 60 (median, 25 days). Primary or secondary graft failure occurred in 16 (6.0%) of 266 evaluable patients (95% CI, 3.5% to 9.6%), each having autologous neutrophil recovery. The estimated day 180 CuIs of grade 2 to 4 and grade 3 to 4 acute GVHD were 33% and 3%, respectively (Fig 1A) . The estimated 1-year CuI of any chronic GVHD was 10% (Fig 1B) . Among all patients age Ն 50 years, the estimated CuI of NRM was 8% at day 180 and 12% at 1 year (Fig 1C) . The 1-year PFS and OS probabilities were 51% and 65%, respectively, with 3-year probabilities of 37% and 46%, respectively (Fig 1D) .
Count Recovery and GVHD
Neutrophil and platelet recovery times were similar among the age groups (Table 2) . On univariable analysis, older patient age was statistically significantly associated with a higher incidence of grade 2 to 4 acute GVHD (Table 2 , Fig 2A) . When stratified by donor age (Ն v Ͻ 40 years) and BMT year, the subdistribution hazard ratio (SDHR) for grade 2 to 4 acute GVHD was statistically significantly higher in patients age Ն 60 years (SDHR, 1.67; 95% CI, 1.05 to 2.65; P ϭ .03) compared with patients age 50 to 59 years. Stratification by donor age Ն 50 versus Ͻ 50 years yielded similar results, as did treating donor age as a continuous covariate (data not shown). No statistically significant association was detected between older patient age (relative to ages 50 to 59 years) and grade 3 or 4 acute or chronic GVHD (Table 2, Fig 2B) .
Nonrelapse Morbidity and NRM
The estimated CuIs of NRM for patients in their 50s, 60s, and 70s were 8%, 9%, and 7%, respectively, at day 180, with 1-year NRM estimates of 9%, 14%, and 11%, respectively (Table 2, Fig 2C; P ϭ .20) . Abbreviations: BMT, blood or marrow transplantation; CuI, cumulative incidence; DFS, disease-free survival; GVHD, graft-versus-host disease; NRM, nonrelapse mortality; OS, overall survival; PFS, progression-free survival.
‫ء‬
P for overall differences between the three age groups based on stratified log-rank or Gray's k-sample tests, with stratification by BMT year (2003 to 2009 v later).
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Given the limited number of patients age Ն 70 years, outcomes in patients age 60 to 75 years (n ϭ 156) were also evaluated. In patients age Ն 60 years, the estimated CuI of NRM was 9% (95% CI, 4% to 13%) at day 180 and 13% (95% CI, 8% to 19%) at 1 year (P ϭ .08 v ages 50 to 59 years). On univariable analysis (Table 4) , patients age Ն 60 years were at higher risk of NRM. However, statistically significant differences were not detected (for age Ն 60 years relative to age 50 to 59 years: SDHR, 1.71; 95% CI, 0.94 to 3.10; P ϭ .08). Univariable analyses of NRM with age as a continuous variable were similar (for every 10-year age increase, SDHR, 1.44; 95% CI, 0.93 to 2.22; P ϭ .10).
In this population, higher HCT-CI risk categories were not statistically significantly associated with greater NRM by predefined risk categories (low, intermediate, or high risk; Table 4), although there was a statistically significant effect with HCT-CI score treated as a continuous variable (data not shown). The effect seemed predominantly confined to HCT-CI scores of Ն 5 relative to lower scores.
Hospitalization data up through day 60 and post-transplantation ECOG PS are shown for descriptive purposes in Appendix Table A1 (online only). The oldest patients were significantly more likely to be electively hospitalized for BMT. In patients not electively hospitalized, the median time to first hospitalization was 9 days, with an associated 3-day median length of stay. Nineteen (7%) of 271 patients were mechanically intubated in the first 60 days after BMT, with no statistically significant difference among patients who received transplantation in their 50s, 60s, and 70s. At approximately 6 months and approximately 1 year after transplantation, the majority of relapse-free patients had an ECOG PS Յ 1. The PS distribution (Յ 1, 2, or Ն 3) at these time points was comparable between the age groups.
Relapse, PFS, and OS
Disease-specific outcomes for the largest groups are listed in Table 3 . In patients with acute myeloid leukemia age Ն 50 years (n ϭ 65), the 3-year probabilities of relapse, PFS, and OS were 52%, 40%, and 49%, respectively (Fig 1E) . In patients with NHL age Ն 50 years (n ϭ 148), including patients with chronic lymphocytic leukemia/ small lymphocytic lymphoma, the 3-year probabilities of relapse, PFS, and OS were 39%, 38%, and 47%, respectively (Fig 1F) . In patients with aggressive B-or T-cell NHL (n ϭ 83), the 3-year estimates of relapse, PFS, and OS were 40%, 39%, and 47%, respectively.
For the group overall, the estimated 3-year CuIs of relapse for patients in their 50s, 60s, and 70s were 48%, 46%, and 41%, respectively (Table 2 , Fig 2D; P ϭ .80). On univariable analysis (Table 4) , there was no statistically significant association between older patient age and relapse risk in this study cohort.
The 3-year PFS probabilities for patients in their 50s, 60s, and 70s were 38%, 35%, and 33%, respectively (Table 2, Fig 2E; P ϭ .65), with 3-year OS probabilities of 48%, 45%, and 44%, respectively (Fig 2F; P ϭ .66). Similar to patients age 50 to 59 years, patients aged Ն 60 years had 1-and 3-year PFS probabilities of 51% (95% CI, 43% to 59%) and 35% (95% CI, 28% to 44%; P ϭ .41), respectively, with OS probabilities of 66% (95% CI, 59% to 74%) and 44% (95% CI, 36% to 54%; P ϭ .36), respectively. In univariable analyses of PFS and OS (Table 4) , no statistically significant association was seen with older patient age treated as either a categorical variable (relative to age 50 to 59 years) or continuous variable.
The DRI was developed to provide a robust tool to improve interpretation of clinical data involving a variety of allogeneic BMT patients and has successfully risk stratified heterogeneous adult patient cohorts across diseases and disease status. 25 In low-, intermediate-, and high-/very high-risk disease groups based on the refined DRI, 25 the 3-year PFS probabilities were 62% (95% CI, 49% to 79%), 36% (95% CI, 29% to 44%), and 15% (95% CI, 7% to 32%; P Ͻ .001), and the 3-year OS probabilities were 68% (95% CI, 55% to 84%), 44% (95% CI, 37% to 53%), and 31% (95% CI, 20% to 49%; P Ͻ .001), respectively. After adjustment for refined DRI group (Table  4) , there remained no statistically significant association between older patient age and PFS, OS, or relapse. Abbreviations: AML, acute myeloid leukemia; BMT, blood or marrow transplantation; DFS, disease-free survival; MCL, mantle-cell lymphoma; NHL, non-Hodgkin lymphoma; OS, overall survival; PFS, progression-free survival.
‫ء‬
Months from BMT to relapse/progression or unplanned treatment of disease persistence in patients with such events. †Including chronic lymphocytic leukemia/small lymphocytic lymphoma. ‡Excluding transformation; 19 patients with indolent B-cell NHL excluding small lymphocytic lymphoma, 21 patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, and 25 patients with MCL.
DISCUSSION
With the increasing life expectancy of the general population, the burden of hematologic cancers is expected to rise substantially, particularly among older adults. 20 By reducing regimen-related toxicity, Notably, this study suggests that advanced age is not associated with prohibitive toxicities in older adults undergoing NMA haplo-BMT with PTCy. In fact, there was no apparent decrement in PFS or OS in patients age Ն 60 years, and even patients age 70 to 75 years, when compared with patients in their 50s. Unquestionably, the older patients were a selected group in that they needed to be otherwise fit for BMT, and it is likely that fewer older patients receive transplants because of comorbidities. However, in older patients who actually underwent BMT, hematopoietic recovery was brisk, with an estimated 90% of all patients age Ն 50 years achieving neutrophil recovery by
Cumulative Incidence
Time After BMT (days) Table 2. day 30 (Table 2 ). The estimated 6-month CuI of NRM was 7% (95% CI, 0% to 17%) in patients age 70 to 75 years and 8% (95% CI, 3% to 13%) in patients age 50 to 59 years. Time-to-event curves for relapse, PFS, and OS were likewise superimposable (Fig 2) . Older donor age may contribute to the higher incidence of grade 2 to 4 acute GVHD observed with increasing patient age. 35 However, the probabilities of severe acute GVHD and any chronic GVHD were low, regardless of age group. In this cohort, relapse rather than toxicity was the leading cause of treatment failure. Rather than older age, disease type and pretransplantation disease status, as determined by the DRI, 25 were key determinants of overall outcome in this study.
The study has a number of limitations, including those inherent to a retrospective single-institution analysis. Selection bias may have influenced inferences from the data. Transplantations in older patients occurred more recently, and regression models, although stratified by BMT year, may not have accounted for some time-related factors. Sample size limitations, particularly for the oldest age group, may mask smaller differences in outcomes, especially for toxicities with relatively low incidences such as NRM. In addition, more comprehensive metrics of transplantation-related toxicity would be helpful, including geriatric assessment measures of functionality, cognition, and quality of life that are best studied prospectively.
36,37 Nevertheless, we find these outcomes in older adults quite encouraging.
NMA haplo-BMT with PTCy seems to produce results in older patients that compare favorably with those reported with NMA or RIC HLA-matched BMT.
33,38-41 For example, in a large Center for International Blood and Marrow Transplant Research analysis of RIC or NMA BMT (Ͼ 90% HLA matched), patients age Ն 40 years had a 33% to 36% probability of acute GVHD, and patients age Ն 65 years had an estimated 1-year NRM of 30% to 35%. 38 In another study of NMA BMT, also more than 90% HLA matched, patients age Ն 60 years had an estimated 1-year NRM of 20%, with no apparent relationship between age group and either NRM or survival. 40 This study suggests that, at least with PTCy-based platforms, NMA haplo-BMT should be considered for older adults who lack HLAmatched donors but who otherwise meet eligibility criteria for BMT. Our institution no longer has an upper age limit for NMA haplo-BMT with PTCy. Strategies to treat and reduce disease relapse are intensively being studied. We found that haploidentical donor lymphocyte infusions have similar effectiveness and toxicity profiles to HLA-matched donor lymphocyte infusions. 42 The favorable toxicity profile of the PTCy platform can also facilitate novel post-transplantation approaches for relapse reduction.
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